Skip to content

Xeris Pharmaceuticals

US · XERS #2862 by market cap Listed 2018
10.11 +0.04 +0.40%
Live - 5344 symbols - heartbeat 488s ago · 2026-10-08 06:44
Pre-market 10.00 -1.09%
After-hours 10.00 -1.09%
Market cap
1.84B
P/E (TTM)
-104.23
P/B
-190.75
EPS
0.00
Reader sentiment Are you bullish or bearish on XERS?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Xeris Pharmaceuticals (XERS) Receives a Buy From H.C. Wainwright
    TipRanks · 2025/9/17
  • Rating change
    TR | OpenAI - 4o Maintains Xeris Pharmaceuticals(XERS.US) With Hold Rating, Raises Target Price to $7.5
    Market Newswire · 2025/8/12
  • Rating change
    H.C. Wainwright Initiates Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $10
    Market Newswire · 2025/8/12
  • Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/9/29
  • Rating change
    Piper Sandler Maintains Xeris Pharmaceuticals(XERS.US) With Hold Rating, Maintains Target Price $8
    Market Newswire · 2026/9/10
  • H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)
    TipRanks · 2026/9/22
  • Rating change
    Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2025/11/7
  • Rating change
    Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $11
    Market Newswire · 2025/8/8
  • Rating change
    Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $9
    Market Newswire · 2025/8/20
  • Rating change
    Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18
    Market Newswire · 2025/10/29
  • Rating change
    Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $9
    Market Newswire · 2026/5/14
  • Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $14
    Market Newswire · 2026/10/6
  • Rating change
    Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
    Market Newswire · 2026/7/1
  • Rating change
    Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $16
    Market Newswire · 2026/9/10
  • Rating change
    Piper Sandler Downgrades Xeris Pharmaceuticals(XERS.US) to Hold Rating, Raises Target Price to $8
    Market Newswire · 2025/11/7
  • Rating change
    Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $8
    Market Newswire · 2025/8/8
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)
    TipRanks · 2026/3/3
  • Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $12
    Market Newswire · 2026/8/20
  • Rating change
    Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $12
    Market Newswire · 2026/7/8
  • H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/9/22
  • Rating change
    Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $7
    Market Newswire · 2025/6/6

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 06:44:43 · For reference only, not investment advice and not tailored to your situation.